Share ownership GlaxoSmithKline plc Liquidnet

GSK

GB0009252882

Pharmaceuticals

Delayed Liquidnet			5-day change	1st Jan Change
- ^EUR	-.--%		-0.40%	-

09:55am	Pharma sector doubles down on AI to slash costs, timelines	RE
03:00am	UK inflation rises; Barratt cuts completions outlook	AN

Share class: GlaxoSmithKline plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,285,440,804	3,974,774,486 ( 92.75 %)	240,019,489 ( 5.601 %)	92.75 %

Major shareholders: GlaxoSmithKline plc

Name	Stocks	%	Valuation
Fidelity Management & Research Co. LLC 5.741 %	232,229,061	5.741 %	5 843 M €
Vanguard Capital Management LLC 2.908 %	117,652,572	2.908 %	2 960 M €
BlackRock Investment Management (UK) Ltd. 2.445 %	98,919,116	2.445 %	2 489 M €
Dodge & Cox 2.195 %	88,816,040	2.195 %	2 235 M €
BlackRock Advisors (UK) Ltd. 1.71 %	69,174,895	1.71 %	1 740 M €
Schroder Investment Management Ltd. 1.633 %	66,042,701	1.633 %	1 662 M €
Norges Bank Investment Management 1.559 %	63,067,000	1.559 %	1 587 M €
Wellington Management Co. LLP 1.537 %	62,169,621	1.537 %	1 564 M €
Geode Capital Management LLC 1.301 %	52,624,922	1.301 %	1 324 M €
Vanguard Asset Management Ltd. 1.266 %	51,231,000	1.266 %	1 289 M €
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Fidelity Management & Research Co. LLC 3.212 %	64,961,481	3.212 %	3 264 M €
Dodge & Cox 2.383 %	48,197,514	2.383 %	2 422 M €
Fisher Asset Management LLC 1.766 %	35,722,792	1.766 %	1 795 M €
PRIMECAP Management Co. 1.245 %	25,182,068	1.245 %	1 265 M €
Wellington Trust Co., NA 0.5634 %	11,396,249	0.5634 %	573 M €
RBC Private Counsel (USA), Inc. 0.4695 %	9,497,477	0.4695 %	477 M €
JTC Employer Solutions Trustee Ltd. 0.4248 %	8,592,987	0.4248 %	432 M €
Eaton Vance Management 0.3786 %	7,657,562	0.3786 %	385 M €
T. Rowe Price International Ltd. 0.3423 %	6,923,642	0.3423 %	348 M €
Acadian Asset Management LLC 0.3293 %	6,660,434	0.3293 %	335 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	59.01%
Others	2.06%
Individuals	0.37%
Aberdeen Group Plc	0.07%
Governments	0.02%
Wärtsilä Oyj Abp	0.01%
Unknown	38.46%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	25.02%
United Kingdom	22.26%
Germany	2.03%
Switzerland	1.95%
Norway	1.74%
Canada	0.96%
Netherlands	0.88%
Italy	0.74%
Japan	0.73%
France	0.72%
Luxembourg	0.64%
Singapore	0.54%
Sweden	0.53%
Individuals	0.37%
South Korea	0.36%
Denmark	0.32%
Spain	0.3%
Australia	0.25%
Ireland	0.23%
Hong Kong	0.19%
Finland	0.15%
Austria	0.12%
Belgium	0.11%
South Africa	0.11%
New Zealand	0.06%
Saudi Arabia	0.05%
Bermuda	0.04%
Taiwan	0.03%
Kazakhstan	0.02%
Kuwait	0.02%
Thailand	0.02%
Qatar	0.01%
Liechtenstein	0.01%
United Arab Emirates	0.01%
China	0.01%

Based on 1000 largest holdings

GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).

Employees

Sector

Pharmaceuticals

Calendar

10-27 Earnings release - Q3 2026

More about the company